NCT06353152

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

An Early Exploratory Clinical Trial of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma.

Detailed description

This study is an open-label, single-/multiple-dose infusion, adaptive dose-escalation designed early exploratory clinical trial aiming to evaluate the safety, tolerability, and efficacy of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection in subjects with CLDN18.2 positive and pathologically confirmed locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma.

Conditions

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection	single-/multiple-dose infusion

Timeline

• Start date: 2023-11-17
• Primary completion: 2025-11-16
• Completion: 2025-11-16
• First posted: 2024-04-08
• Last updated: 2024-04-08

Locations

1 site across 1 country: China